cyrilzakka/clinical-trials huggingface dataset:
National Retrospective Study of Duodenal Trauma

Duodenal injuries remain rare among abdominal trauma, concerning less than 5 % of cases. However, due to its central location, it is most commonly associated with multiple organs lesions, with the main three organs being the liver, the colon and the pancreas. Additionally, the penetrating mechanism is four times more common than blunt trauma and the most common duodenal site of injury is the second portion (36 %), the least being the first duodenum (13 %). These particularities generate a high morbidity, ranging from 22 to 27.1 %, and a mortality still as high as 5.3 to 30 % today. When facing it, surgeons are usually challenged in their strategy. Indeed, when surgery is required, different options can be chosen depending on the grade of the lesion and the involvement of the papilla and/or other organs. Primary repairs, duodenal diverticulization, pyloric exclusion, gastrojejunostomy, retrograde duodenostomy, distal feeding tube, or even resection and Whipple procedures, have all been described. Since the classification of the American Association for the surgery of trauma (AAST), most studies stratified their management as such: drainage only or primary repair for grade 1 and 2, jejunostomy and/or pyloric exclusion for grade 3, Whipple for grade 4 or 5. However, reviews of the literature aren't clear if this decisional tree is in correlation with lower morbidities, and often different procedures have been reported for the same grade. The escalation of technical exclusions among severe grades became controversial. As an example, pyloric exclusion has been criticized in its preventive role of protecting the suture, being useless at least, or even worse at times. Thus, in the recent years, the management has been focused towards minimization. Indeed, in the retrospective review of the Pan-American trauma society primary repair alone was performed in 80 % of cases, all grades comprised. Although mortality was high, duodenal suture line leak was statistically lower among survivors over every grade.

To clear the situation, prospective studies are difficult if not impossible in such context. Thus, The investigators propose this national benchmark, to retrospectively review in France the management of duodenal trauma, depending on the grade, and its associated morbidity.


Eligibility Criteria:
Inclusion Criteria:

* patients with duodenal trauma,
* older than 18 years old.

Exclusion Criteria:

* pregnancy
* previous duodenal surgery.
* Associated surrounding organs trauma, was not an exclusion criterion, but duodenal trauma must have been one of the main injuries.
Effects of Isolated Rooms on the Prevalence of Hospital Acquired Pneumonia in a Respiratory ICU

This study will carry out in the ICU. Objectives of the study are to determine the frequency of HAP and the effect of isolated rooms on the frequency of pneumonia in the ICU.

In the present study, it was aimed to determine the incidence, causative agents, antimicrobial resistance, and risk factors for lower respiratory tract infections in patients followed in the ICU for the last 4 years. The effect of reconfiguration from a ward-type ICU consisting one large room to an ICU with isolated rooms with two beds on the incidence of HAP was also determined.

Eligibility Criteria:
Inclusion Criteria:

* adult patients,
* admitted to the ICU

Exclusion Criteria:

* trauma, surgery or burned patients
* patients under 18
Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

The investigators hypothesized that combined pharmacotherapy using adjunctive aripiprazole of standard antidepressants would be associated with improved depression response in Major depressive disorder, especially in Quality of life.

The investigators compare the mean changes in the quality of life between before add-on and 8 weeks treatment of aripiprazole and between before add-on and 6 weeks treatment of aripiprazole.

Previous study about quality of life measurement in patients with depression have been reported that quality of life have to be measured irrespective with the severity of depression because quality of life has some other aspect to depression.The investigators have designed a 6-week single blinded study with flexible dose aripiprazole augmentation, ranging from 2.5mg to maximum 20 mg (15mg for patients on fluoxetine or paroxetine), in patients who responded inadequately (a score of \>18 on the MADRS) to first-line antidepressant pharmacotherapy. The investigators compare the mean changes from in the quality of life at 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Age : 18-65
* Patients with major depressive disorder according to DSM-IV criteria that have lasted \>8 weeks
* MADRS total score of 18 or higher
* Patients who responded inadequately (a score of \>18 on the MADRS) to first-line antidepressant treatment of 4 week duration
* Current use of standard antidepressant treatment in monotherapy or combination of 2 antidepressants : escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d)

Exclusion Criteria:

* Past history of hypersensitivity to aripiprazole
* Primary diagnosis of MDD with psychotic feature, bipolar disorder, schizophrenia, schizoaffective disorder, other psychotic disorder or anxiety disorder, a history of alcohol/ drug abuse within the past 12 months, or a diagnosis of dementia
* Clinically significant current Axis II (DSM-IV-TR) diagnosis
* A significant risk of suicide corroborated by a score of ≥5 on item 10(suicidal thoughts) on the MADRS scale or by clinical judgment of the investigator
* Pregnancy or in breast-feeding
* Presence of a serious medical illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease or physical disorder judged to significantly affect central nervous system function
* Patients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics
* Patients with past treatment failures of aripiprazole
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

This is a long-term follow-up to an earlier study, LA38-0411. Its purpose is to gather more information about the safety and efficacy of deferiprone in patients with sickle cell disease or other anemias who suffer from iron overload caused by regular blood transfusions.

Deferiprone (brand name Ferriprox®) is an iron chelator that is approved in the United States and over 60 other countries for the treatment of iron overload in patients with thalassemia, when other treatments are inadequate. This study has been designed to evaluate the long-term efficacy, safety, and tolerability of deferiprone to treat iron overload in patients who have sickle cell disease or other anemias.

Only patients who have completed an earlier study, LA38-0411, are eligible to enroll in this one.

Eligibility Criteria:
Inclusion Criteria:

1. Completed study LA38-0411
2. Females of childbearing potential must have a negative pregnancy test result at Visit 1. In addition, if applicable, they must:

   * Use an effective method of contraception according to local requirements, during the study and within 30 days following their last dose of study medication, OR
   * Have had a tubal ligation (supporting evidence required), OR
   * Have had a hysterectomy (supporting evidence required), OR
   * Participate in a non-heterosexual lifestyle, OR
   * Have a male sexual partner who has been sterilized (supporting evidence required)
3. Fertile heterosexual males and/or their partners must agree to use an effective method of contraception during the study and for 30 days following the last dose of study medication
4. All patients and/or their authorized legal representatives must provide signed and dated written informed consent prior to the first study intervention, and assent will be obtained from patients who are considered to be minors. Patients must be able to adhere to study restrictions, appointments, and evaluation schedules.

Exclusion Criteria:

1. Plan to participate in another clinical trial at any time from the day of enrollment until 30 days post-treatment in the current study
2. For only those patients who were treated with deferoxamine in study LA38-0411 (Group 2): Presence of any medical condition (including clinically significant laboratory abnormalities, such as ALT (alanine aminotransferase) ≥ 5 x ULN or creatinine ≥ 2 x ULN), psychological condition, or psychiatric condition which in the opinion of the investigator would cause participation in the study to be unwise.
3. Pregnant, breastfeeding, or planning to become pregnant during the study period.
4. Treatment failure after 1 year on deferiprone which in the investigator's judgment indicates the need for the patient to be started on a different iron chelator
Predictive Value of Mid-luteal Serum Progesterone Levels in Egg Donation Cycles

This study aims to investigate the impact of serum progesterone concentrations on the day of embryo transfer in egg donation cycles under hormonal replacement therapy. As secondary outcomes, the investigators will investigate if endometrial volume measured by three-dimensional (3D) ultrasound on the day of embryo transfer is related with progesterone levels and with chances of pregnancy.


Eligibility Criteria:
Inclusion Criteria:

* Age\<50 yo
* BMI \< 30Kg/m2
* Hormonal replacement cycle
* Endometrial thickness \>6.5 mm during proliferative phase
* Transfer of one or two blastocyst grade A-B according to ASEBIR

Exclusion Criteria:

* Uterine pathology
* Cryptozoospermia
* Severe implantation failure (\>6 GQ embryos transferred without success)
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development

To investigate the role of ATP sensitive K+ potassium channels and the Na+/K+ pump in the development of fatigue in healthy and in insulin resistant subjects.


Eligibility Criteria:
Inclusion Criteria:

* Non smokers
* HbA1c \<38 mmol/mol (\<5.7%), HOMA-IR \> 1.7 (insulin resistant)
* VO2max \<40 ml/kg/min (insulin resistant), 45-55 ml/kg/m2 (healthy)
* BMI \>26 kg/m2 (insulin resistant), 19-26 kg/m2 (healthy)

Exclusion Criteria:

* Use of antidiabetic medication or any other medication deemed to interfere with study outcomes
* Allergy towards Nicorandil
* Chronic disease other than type 2 diabetes deemed to interfere with study outcomes
* Excessive alcohol consumption (\>14 units/week)
* Abnormal ECG
D-chiro-inositol Increases Androgens and Reduces Estrogens in Human Serum

The aim of this pilot study is to test the effect of a 30 day-D-chiro-inositol oral treatment on a set of clinical parameters (mainly sex hormones) in a group of male volunteers selected by their age and BMI to investigate if D-chiro-inositol acts as an aromatase inhibitor.

This is an open label clinical trial with a dietary supplement carried out in male volunteers selected by their age and BMI. The aim is to test the effect of oral daily treatment with 1 g D-chiro-inositol for 30 days on some clinical parameters, to see if D-chiro-inositol acts as an aromatase inhibitor. Testosterone, estradiol, Testosterone/Estradiol ratio, Dehydroepiandrosterone sulfate, Estrone, glycemia and insulinemia (with calculation of HOMA index), follicle-stimulating hormone, Luteinizing hormone, D-chiro-inositol and Myo-inositol serum concentrations have to be determined before and after D-chiro-inositol administration.

We wish to evaluate if this treatment for one month is able to change the sexual hormone levels, increasing androgens and decreasing estrogens. Furthermore, we wish to control the safety profile of D-chiro-inositol, a well-known molecule, different from the classic aromatase inhibitors. We think that our pilot study can open up new perspectives of research and therapeutic applications for this many-sided molecule.

Eligibility Criteria:
Inclusion Criteria:

* Body mass index (BMI) range is between 22 and 34 kg/m2, in order to include subjects with normal weight, overweight and obese. Subjects with altered glycemia or hormonal status due to age or weight were enrolled in the study.

Exclusion Criteria:

* Men with poor general health were excluded from the study.
Covid-19 Long-term Revalidation Follow-up

In this monocentric, prospective and descriptive trial we want to evaluate the long-term consequences for patients treated for Covid-19. Covid patients who were hospitalized for min. 5 days either in a Covid-19 department or in intensive care unit will be followed-up for 8 weeks after hospital discharge. This is done via an innovative electronic platform in the home environment (UZA@home). On the one hand the quality of life, rehabilitation and reintegration of the patient will be evaluated and on the other hand the patient will be screened for various psychosocial aspects such as anxiety, depression and post-traumatic stress syndrome.


Eligibility Criteria:
Inclusion Criteria:

* Males and females
* Adult age
* Hospitalization with proven Covid-19 infection with a minimum stay of 5 days
* Signed Informed Consent

Exclusion Criteria:

* The patient does not have a smartphone or computer with internet connection.The patient is not sufficiently skilled in entering data via a digital interface. This degree of skill is estimated by the research doctor or nurse.
* Patient in a palliative setting (DNR 2 or higher outside of COVID condition
* The patient does not speak the Dutch language
Risk Evaluation by COronary CTA and Artificial intelliGence Based fuNctIonal analyZing tEchniques - I

This study is a multicenter, retrospective imaging study. The study intends to retrospectively enroll patients with acute myocardial infarction who had received coronary CTA in a certain time-window before this event. All coronary CTA will be analyzed by anatomic, functional and radiomic analysis, assisted by artificial intelligence. The purpose of this study is to establish a coronary artery disease risk stratification system by coronary CTA.

Coronary angiography has been the gold standard for the diagnosis of coronary heart disease and PCI decision-making. However, the value of CAG in risk stratification is limited due to its invasive nature and lack of ability to evaluate coronary physiology and plaque characteristics, which often leads to over-treatment or under-treatment. In recent years, with the development and improvement of imaging technology, the resolution and diagnostic accuracy of coronary artery CTA have been greatly improved, and the subsequent anatomy and function (non-invasive CT-FFR, etc.) have made the assessment of coronary artery lesion risk multi-dimensional. Comprehensive and accurate coronary artery CTA scan plays a positive role in establishing the appropriate standard for PCI and improving the prognosis of patients. However, the existing problems of coronary artery CTA are insufficient imaging studies, complex image analysis, inconsistent diagnostic criteria, and insufficient clinical evidence. This study is one of the series of clinical studies on the topic of "Risk Evaluation by COronary Computed Tomography and Artificial Intelligence Based fuNctIonal analyZing tEchniques (RECOGNIZE)". The purpose of the study is to establish a coronary artery disease risk stratification system by coronary CTA and anatomic, functional and radiomic analysis, assisted by artificial intelligence.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18-80 years old
* Received coronary CT angiography 3 months to 5 years prior to acute coronary myocardial infarction. CCTA identified coronary atherosclerotic plaques with diameter stenosis ≥ 10%

Exclusion Criteria:

* Familial hypercholesterolemia
* Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
* Prior history of myocardial infarction before the recent event
* Severe liver or renal insufficiency
Real-world Clinical Study and Medical Machine Intelligence Study for Traditional Chinese Internal Medicine

This real-world study aimed at 1. exploring the relationships of traditional Chinese medicine (TCM) syndrome and internal diseases, 2. investigating the relationships of TCM treatment and internal diseases, and 3. creating medical machine intelligence to help internal physician in clinical practice. Big data methods and artificial intelligence algorithms are used to assess the associations based on electronic case files of patients.


Eligibility Criteria:
Inclusion Criteria:

* all patient records of internal medicine in hospital

Exclusion Criteria:

* subjects with major missing data
Evaluation of GCF And Salivary Ferritin, ALP And MMP-8 Levels of Individuals With Different Periodontal Diseases

The aim of this clinical study was to determine the levels of ferritin, alkaline phosphatase and matrix metalloproteinase-8 in the gingival crevicular fluid (GCF) and saliva samples were collected from 60 systemically healthy, non-smoker periodontitis (P group, n = 20), gingivitis (G group, n = 20) and periodontally healthy individuals (S group, n = 20) and all clinical parameters were recorded for all groups at baseline. GCF and serum samplings and clinical records were also repeated at 1st and 3rd months visitsfor only P group. Ferritin, MMP8, and ALP levels in samples were determined by enzyme-linked immunosorbent assay (ELISA).


Eligibility Criteria:
Inclusion Criteria:

* Systemically healthy
* At least twenty permanent teeth in the mouth
* Non-smoker
* No medication for continuous use
* Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
* Not in pregnancy or lactation period.
* For the periodontitis group that has not received periodontal treatment in the last 6 months

  * For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss
  * For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss
  * For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.

Exclusion Criteria:

* Any oral or systemic disease
* Regularly using a systemic medication
* During pregnancy or lactation
* Received periodontal treatment within the last 6 months.
* Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months
* Smokers are not included in the study
Customized Acoustic Stimulation for the Treatment of Tinnitus

The purpose of this study is to determine the efficacy of a customized sound therapy in reducing tinnitus loudness and increasing the residual inhibition.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* Male or female
* Tinnitus present for 6 months or more
* Adequate command of English

Exclusion Criteria:

* Active illicit drug use, alcohol dependence
* Treatable cause of tinnitus
* History of psychosis
* Subjects on medications known to cause tinnitus (aspirin, ibuprofen, naproxen) which could not be stopped will be excluded.
Radiation Dose Audit Reports to Reduce Radiation Exposure From CT Exams

The purpose of this study is to quantify variation in radiation dose levels across CT technologists, and determine the effectiveness of combining radiation dose audit reports and an educational seminar as a means to reduce the variation and level of patient exposure to radiation.

The investigators expect the radiation dose audit reports and educational seminar will lead to reduced radiation exposure to patients by making technologists more aware of the risks of radiation exposure from CT exams and identifying technologists with higher radiation exams compared with their peers.

The investigators expect the degree to which a technologist is concerned and aware about radiation exposure and cancer risk will be associated with adherence to radiation reduction protocols and the subsequent level of radiation their patients are exposed to when receiving a CT examination.

The use of advanced diagnostic imaging has increased dramatically over the past decade, not only contributing to rising medical costs but also exposure to ionizing radiation, of which CT imaging plays a prominent role because it requires a relatively high dose of radiation to produce an image when compared to conventional X-rays. The growth in the use of CT imaging along with all other advanced medical imaging has been well documented, and taken as a whole the use of these services has grown quicker than all other services provided by physicians. Research has also shown great variability in the amount of radiation exposure to individual patients, even when patient and other characteristics are controlled for. Given the increase in the use of CT imaging and the variability in radiation exposure between similar imaging exams, it is important to study ways of standardizing and reducing radiation levels from CT imaging. Little is understood about the role of CT technologists' attitudes and how they may influence patient radiation exposure, therefore, this project also give us the opportunity to survey the technologists and determine if there is a relationship between technologist attitudes and awareness and the radiation exposure of patients.

Eligibility Criteria:
Inclusion Criteria:

* Group Health CT Technologist from Capitol Hill, Tacoma and Bellevue Clinics

Exclusion Criteria:

* None